July is Dry Eye Awareness Month, but the key opinion leaders who blog for Healio.com/OSN keep readers updated on the top dry eye news throughout the year.
Here are four dry eye blogs to keep you up to date:
BLOG: Managing the asymptomatic dry eye patient: Tips for every doctor
We’ve made so much progress in our knowledge, diagnosis and treatment of dry eye and its most common cause, meibomian gland dysfunction. Today, with all our current capabilities, it can be frustrating for doctors to detect dry eye not (Read more...)
Author: Healio ophthalmology
In phase 1 study, ICON-1 intravitreal injections safe in eyes with neovascular AMD
Intravitreal injections of ICON-1 in eyes with neovascular age-related macular degeneration were found to be safe and well-tolerated in doses up to 300 µg.
The open-label, interventional, dose-escalation phase 1 trial included 18 patients with choroidal neovascularization due to neovascular AMD. Each dose cohort included six patients, with patients receiving a single intravitreal injection of ICON-1 (Iconic Therapeutics) at doses of 60 µg, 150 µg or 300 µg.
“This is the first clinical report of a novel mechanism in the treatment of neovascular AMD, distinct from
FDA warns against using sterile drugs from Ranier’s Compounding Laboratory
The FDA is warning health care professionals not to use sterile drug products from Ranier’s Compounding Laboratory due to lack of sterility assurance.
Medical supplies should immediately be checked, and any purportedly sterile drug products from the Jeannette, Pennsylvania, laboratory and pharmacy should be quarantined and not administered to patients, according to an FDA release.
A warning letter was sent to the facility in March 2017 after an inspection found “serious deficiencies” in sterile drug production practices, which could put patients at risk. In June, the FDA
Organizations to hold congressional dry eye briefing
To mark Dry Eye Awareness Month and highlight the 2017 publication of the Tear Film & Ocular Surface Society’s Dry Eye Workshop II, TFOS and the Alliance for Eye and Vision Research will host a congressional briefing today.
Moderated by David Sullivan, MS, PhD, FARVO, the briefing will include panelists Janine Austin Clayton, MD, OSN Cornea/External Disease Board Member Penny A. Asbell, MD, Leslie O’Dell, OD, FAAO, and Scott Schachter, OD. They will discuss how TFOS DEWS II has affected clinical perspectives of dry eye disease, according to a release (Read more...)
OCTANe recaps highlights of Ophthalmology Technology Summit
OCTANe’s Ophthalmology Technology Summit, which aims to bring together ophthalmology experts and entrepreneurs to discuss technology and business opportunities, grew by 35% this year, with more than 400 people in attendance, according to a press release.
The meeting was chaired by Jim Mazzo, global president of ophthalmic devices at Carl Zeiss Meditec, OSN Cataract Surgery Section Editor John A. Hovanesian, MD, FACS, OSN Cornea/External Disease Section Editor Elizabeth Yeu, MD, and Ehsan Sadri, MD, FACS, of Atlantis Eyecare in California, and featured panels on innovation, business and
Women in Ophthalmology Summer Symposium to focus on scientific innovations, burnout and leadership skills
The Women in Ophthalmology 2018 Summer Symposium will take place in Ponte Vedra Beach, Florida, from Aug. 16 to 19 and will focus on scientific innovations, wellness, leadership skills and self-care.
“It is a unique meeting created by women, for women, for the advancement of women,” Regine Pappas, MD, WIO development chair, told Healio.com/OSN. “It provides attendees with an intimate environment where we focus on self-improvement as well as career goals.”
The WIO Summer meeting emphasizes cutting-edge scientific ophthalmic sessions with more than 20 hours of CME, 100
FTC approves Takeda’s Shire acquisition
The U.S. Federal Trade Commission has approved Takeda Pharmaceutical’s acquisition of Shire, according to a press release.
The FTC issued an unconditional clearance of the takeover, which is still subject to other conditions, including other regulatory clearances and shareholder approval, the release said.
Takeda announced in May it would acquire Shire for approximately 46 billion pounds, or 49.01 pounds per Shire share.
Biometric measurements led to more accurate IOL power calculations
The use of an optical biometer for biometric measurements led to accurate IOL power calculations for several IOL power formulas.The prospective interventional multicenter study included 118 eyes of patients undergoing cataract surgery. Researchers eval…
Top five videos from OCTANe Ophthalmology Technology Summit
The OCTANe Ophthalmology Technology Summit took place in Newport Beach, California, on June 29, bringing together key opinion leaders in ophthalmology, industry and technology.
Healio.com/OSN featured video perspectives from the meeting. Here are the top five most-viewed videos from OTS 2018:
Novaliq preps dry eye products for entry into US market
Bernhard Günther, co-founder of Novaliq GmbH and president of Novaliq Inc., discusses the company’s progress in bringing products for treating dry eye disease to the U.S. Watch here.
Presbyopia-correcting treatments, MIGS entering
FDA clears Alleye AMD monitoring application
The FDA has issued 510(k) clearance of Alleye, a mobile medical software application, Oculocare medical announced in a press release.
Alleye is designed to detect and monitor age-related macular degeneration and characterize central and paracentral metamorphopsia, the release said.
“We are very excited about the FDA clearance, which will help millions of patients with AMD to better manage their health by monitoring their eyesight,” Lucas Bachmann, Oculocare CEO and co-founder, said in the release.
Oculocare is planning to market Alleye in the United States through pharmaceutical or
FDA accepts NDA for loteprednol etabonate ophthalmic gel 0.38%
A new drug application for Bausch + Lomb’s sub-micron loteprednol etabonate ophthalmic gel 0.38% has been accepted by the FDA, the company announced.
If approved, it would be the lowest concentrated loteprednol ophthalmic corticosteroid for the treatment of postoperative inflammation and pain after ocular surgery, according to a press release.
“The sub-micron loteprednol etabonate ophthalmic gel 0.38% will offer eye care professionals and their patients a lower concentration formulation with less frequent dosing compared to currently available formulations of loteprednol,”
VIDEO: Foundation progresses in fighting inherited retinal diseases
NEWPORT BEACH, Calif. — Jason Menzo, chief operating officer of the Foundation Fighting Blindness, the leading private funder of research for inherited retinal diseases, discusses progress the organization has helped fund, such as the approval of Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics). To find out more about clinical trials ongoing in the inherited retinal disease space, go to www.blindness.org.
Physicians reporting burnout twice as likely to make medical mistakes
Physicians with burnout reported medical errors at double the rate of other clinicians after adjusting for specialty, work hours, fatigue and work unit safety rating, according to findings recently published in Mayo Clinic Proceedings.
“A nuanced understanding of the potentially bidirectional connection between physician well-being and patient safety remains in its infancy,” Daniel S. Tawfik, MD, of the department at pediatrics at Stanford University and colleagues wrote.
Researchers reviewed survey responses from 6,695 actively practicing physicians, of whom 55% reported burnout
VIDEO: Top three trends in eye care delivery
NEWPORT BEACH, Calif. ― John A. Hovanesian, MD, discusses three trends in ophthalmic health care delivery that came out of a panel discussion during OCTANe’s Ophthalmology Technology Summit.
VIDEO: OCTANe OTS covers ophthalmology innovation A to Z
NEWPORT BEACH, Calif. ― Ehsan Sadri, MD, discusses the many topics encompassing innovation in ophthalmology covered during OCTANe’s Ophthalmology Technology Summit here.
June’s top 5 retina stories
June’s most read articles focusing on retina news included breaking news regarding a new IOL for patients with AMD, as well as regulatory and business updates.
Here are the top 5 most popular retinal articles of the month on Healio.com/OSN:
Magnifying lens improves vision, quality of life in patients with advanced AMD and cataract
A foldable design makes the lens implantable through a small incision, similar to a normal IOL. Read more.
Bevacizumab used more frequently than ranibizumab for Medicare beneficiaries with DME
In a sample of Medicare (Read more...)
VIDEO: Novaliq preps dry eye products for entry into US market
NEWPORT BEACH, Calif. ― At OCTANe’s Ophthalmology Technology Summit, Bernhard Günther, founder and chief innovation officer for Novaliq Inc., discusses the company’s progress in bringing products for treating dry eye disease to the U.S.
Katena acquires Blink Medical
Katena Products has acquired the U.K.-based single use ophthalmic instrument provider Blink Medical Ltd., the company announced in a press release.
“The acquisition of Blink Medical strengthens and expands Katena’s offering in high quality ophthalmic instrumentation,” Katena CEO Mark J. Fletcher said in the release. “Single use instruments are important to our strategy and the addition of Blink also offers Katena the benefits of a physical presence in Europe.”
Currently Blink Medical distributes products in Europe and the Middle East, according to the press
VIDEO: CEDARS/ASPENS, OCTANe partnership to drive new innovations
NEWPORT BEACH, Calif. ― Mitchell A. Jackson, MD, president of the CEDARS/ASPENS group of anterior segment surgeons, discusses the recent collaboration agreement between the group and OCTANe, which will drive closer integration of the key opinion leaders and industry in the early adoption of new technologies.
Phakic lens in high myopes yields early refractive stability
A 3-month prospective study carried out at a Chinese university showed safety, efficacy and stability of results with the implantation of a posterior chamber phakic ICL in highly myopic eyes.The Staar Surgical ICL V4c has a central hole that enhances a…